Hepatitis C - Competitive Landscape, Market and Pipeline Analysis 2017, report provides comprehensive insights about different therapeutic drugs for the treatment of Hepatitis C.
Introductionss
Collaborations
Technology
Overview
Signs and Symptoms
Pathogenesis
Diagnosis
Marketed Drugs
Vosevi: Gilead Sciences
Product Description
Research and Development
Product Development Activities
Drug Sales
Daklinza: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug Sales
Ximency: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Sunvepra: Bristol-Myers Squibb
Product Description
Research and Development
Product Development Activities
Drug Sales
Pegasys: Roche
Product Description
Research and Development
Product Development Activities
Drug Sales
Sovaldi: Gilead Sciences
Product Description
Research and Development
Product Development Activities
Drug Sales
Other Marketed Drug Profiles in detailed report
Clinical Pipeline Landscape
Comparative Analysis
Late Stage Products (Filed & Phase III)
Comparative Analysis
Danoprevir: Roche
Product Description
Research and Development
Product Development Activities
Glecaprevir/Pibrentasvir (G/P): AbbVie
Product Description
Research and Development
Product Development Activities
Other Drug Profiles in detailed report
Mid Stage Products (Phase II)
Comparative Analysis
JNJ-4178: Janssen
Product Description
Research and Development
Product Development Activities
P-1101: PharmaEssentia
Product Description
Research and Development
Product Development Activities
Other Drug Profiles in detailed report
Early Stage Products (Phase I)
Comparative Analysis
AVR560: AllaChem
Product Description
Research and Development
Product Development Activities
CC-31244: Cocrystal Pharma
Product Description
Research and Development
Other Drug Profiles in detailed report
Pre-clinical and Discovery
Therapeutic Assessment: Clinical Pipeline Products
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Stage and Molecule Type
Inactive Products
Dormant Products
Comparative Analysis
Discontinued Products
Comparative Analysis
Drivers and Barriers
Appendix
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Table 1: Total Products for Hepatitis C
Table 2: Late Stage Products (Filed and Phase III)
Table 3: Mid Stage Products (Phase II)
Table 4: Early Stage Products (Phase I)
Table 5: List of Pre-clinical and Discovery Products
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Therapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: List of Discontinued Products
Figure 1: Course of Illness with Hepatitis C
Figure 2: Global Epidemiology of Hepatitis C
Figure 3: HCV Life Cycle and Pathogenesis
Figure 4: Vosevi, Historical & Forecasted Sales (million USD)
Figure 5: Daklinza, Historical & Forecasted Sales (million USD)
Figure 6: Sunvepra, Historical & Forecasted Sales (million USD)
Figure 7: Pegasys, Historical & Forecasted Sales (million USD)
Figure 8: Sovaldi, Historical & Forecasted Sales (million USD)
Other Marketed Drug Sales in detailed report (Figure 9-19).
Figure 20: Total Products for Hepatitis C
Figure 21: Late Stage Products (Filed and Phase III)
Figure 22: Mid Stage Products (Phase II)
Figure 23: Early Stage Products (Phase I)
Figure 24: Pre-clinical and Discovery Products
Figure 25: Assessment by Monotherapy Products
Figure 26: Assessment by Combination Therapy Products
Figure 27: Assessment by Route of Administration
Figure 28: Assessment by Stage and Route of Administration
Figure 29: Assessment by Stage and Molecule Type
Figure 30: Dormant Products
Figure 31: Discontinued Products
Phone
India: +91-11-45689769, +91-9650213330Address
New Delhi-110075, IndiaAddress
304 S. Jones Blvd #2432, Las Vegas NV 89107Phone
Outside India: +1(919)321-6187Copyright © 2018 Delveinsight.